Squarepoint Ops LLC Phathom Pharmaceuticals, Inc. Transaction History

Squarepoint Ops LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$9.18 - $11.53 $202,969 - $254,928	-22,110 Reduced 64.26%	12,296 $137,000
Q3 2022 Nov 14, 2022	BUY	$6.46 - $12.11 $119,697 - $224,386	18,529 Added 116.7%	34,406 $381,000
Q2 2022 Aug 15, 2022	BUY	$6.2 - $15.5 $98,437 - $246,093	15,877 New	15,877 $134,000
Q2 2021 Aug 16, 2021	SELL	$32.66 - $39.87 $365,334 - $445,985	-11,186 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$33.86 - $48.68 $588,723 - $846,399	-17,387 Reduced 60.85%	11,186 $420,000
Q4 2020 Feb 16, 2021	BUY	$33.22 - $50.26 $949,195 - $1.44 Million	28,573 New	28,573 $949,000

158

68.4M

52.3K

635K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $153M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.